Pacira BioSciences, Inc. (PCRX): Price and Financial Metrics


Pacira BioSciences, Inc. (PCRX)

Today's Latest Price: $50.07 USD

0.08 (0.16%)

Updated Feb 18 8:00pm

Add PCRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 215 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

PCRX Stock Summary

  • With a one year PEG ratio of 1,930.38, Pacira BioSciences Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 97.48% of US stocks.
  • With a price/earnings ratio of 822.23, Pacira BioSciences Inc P/E ratio is greater than that of about 99.42% of stocks in our set with positive earnings.
  • The price/operating cash flow metric for Pacira BioSciences Inc is higher than 83.9% of stocks in our set with a positive cash flow.
  • Stocks that are quantitatively similar to PCRX, based on their financial statements, market capitalization, and price volatility, are CRY, PODD, SSTI, MTLS, and GRUB.
  • PCRX's SEC filings can be seen here. And to visit Pacira BioSciences Inc's official web site, go to www.pacira.com.
PCRX Daily Price Range
PCRX 52-Week Price Range

PCRX Stock Price Chart More Charts


PCRX Price/Volume Stats

Current price $50.07 52-week high $51.00
Prev. close $49.99 52-week low $34.64
Day low $49.98 Volume 516,700
Day high $50.67 Avg. volume 475,559
50-day MA $45.22 Dividend yield N/A
200-day MA $42.40 Market Cap 2.09B

Pacira BioSciences, Inc. (PCRX) Company Bio


Pacira Pharmaceuticals develops, commercializes, and manufactures proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. The company was founded in 2006 and is based in Parsippany, New Jersey.

PCRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$50.07$176.18252%

We started the process of determining a valid price forecast for Pacira BioSciences Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Pacira BioSciences Inc ranked in the 80st percentile in terms of potential gain offered. Specifically, our DCF analysis implies the stock is trading below its fair value by an estimated 254.17%. As for the metrics that stood out in our discounted cash flow analysis of Pacira BioSciences Inc, consider:

  • The company's compound free cash flow growth rate over the past 4.71 years comes in at 0.81%; that's greater than 89.62% of US stocks we're applying DCF forecasting to.
  • Pacira BioSciences Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than just 0% of US stocks with positive free cash flow.
  • The weighted average cost of capital for the company is 9. This value is greater than 77.91% stocks in the Healthcare sector that generate free cash flow.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%246%
1%249%
2%252%
3%256%
4%259%
5%263%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as PCRX, try CCEL, QDEL, AMS, ACHC, and ABC.


PCRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

PCRX Latest Social Stream


Loading social stream, please wait...

View Full PCRX Social Stream

PCRX Price Returns

1-mo N/A
3-mo 13.59%
6-mo 37.03%
1-year 25.36%
3-year 14.58%
5-year -57.33%
YTD 10.53%
2019 5.30%
2018 -5.76%
2017 41.33%
2016 -57.94%
2015 -13.39%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.6349 seconds.